IRIS
PASSAMONTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.424
AS - Asia 3.211
EU - Europa 2.602
SA - Sud America 357
Continente sconosciuto - Info sul continente non disponibili 123
AF - Africa 97
OC - Oceania 7
Totale 10.821
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.314
CN - Cina 1.625
SG - Singapore 648
IE - Irlanda 500
UA - Ucraina 384
HK - Hong Kong 362
FI - Finlandia 296
DE - Germania 282
BR - Brasile 247
IT - Italia 247
VN - Vietnam 246
RU - Federazione Russa 238
FR - Francia 220
SE - Svezia 152
GB - Regno Unito 138
IN - India 76
BD - Bangladesh 52
CA - Canada 48
ZA - Sudafrica 38
AR - Argentina 37
MX - Messico 36
PK - Pakistan 32
NL - Olanda 31
PL - Polonia 28
IQ - Iraq 24
JP - Giappone 23
CO - Colombia 18
EC - Ecuador 18
BE - Belgio 15
TR - Turchia 14
ID - Indonesia 13
SA - Arabia Saudita 13
ES - Italia 12
JO - Giordania 11
PY - Paraguay 11
VE - Venezuela 11
MY - Malesia 10
AT - Austria 9
LT - Lituania 9
PH - Filippine 8
TN - Tunisia 8
AU - Australia 7
CL - Cile 7
KE - Kenya 7
MA - Marocco 7
MU - Mauritius 7
AL - Albania 6
EU - Europa 6
NP - Nepal 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
EG - Egitto 5
JM - Giamaica 5
CH - Svizzera 4
CR - Costa Rica 4
DZ - Algeria 4
GA - Gabon 4
GR - Grecia 4
NG - Nigeria 4
PA - Panama 4
PE - Perù 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
ET - Etiopia 3
GT - Guatemala 3
IL - Israele 3
IR - Iran 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AZ - Azerbaigian 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
EE - Estonia 2
GP - Guadalupe 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LV - Lettonia 2
LY - Libia 2
OM - Oman 2
QA - Qatar 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
UY - Uruguay 2
AO - Angola 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
Totale 10.690
Salva come PNG Salva come JPEG
Città #
Chandler 548
Dublin 500
Jacksonville 470
San Jose 377
Hong Kong 358
Nanjing 352
Ashburn 335
Singapore 326
Dallas 298
Beijing 255
Boardman 191
Lauterbourg 167
Council Bluffs 137
Nanchang 135
Los Angeles 119
Hebei 116
Princeton 112
Shenyang 109
Lawrence 108
Medford 102
New York 102
Wilmington 102
Changsha 99
Ann Arbor 84
Ho Chi Minh City 84
Jiaxing 69
Helsinki 64
Tianjin 62
Hanoi 55
Hangzhou 54
Milan 53
Santa Clara 46
Munich 42
Buffalo 41
Shanghai 38
Woodbridge 38
Orem 36
Moscow 34
Redondo Beach 34
Johannesburg 30
Warsaw 22
Tokyo 21
Turku 20
Rome 19
San Francisco 17
São Paulo 17
Norwalk 16
Verona 16
Brussels 15
Chennai 15
Rawalpindi 15
Toronto 15
Des Moines 14
Fairfield 13
Nuremberg 13
Pavia 13
Seattle 13
The Dalles 13
Da Nang 12
Falkenstein 12
Manchester 12
Mexico City 12
Montreal 12
Auburn Hills 11
Amman 10
Atlanta 10
Baghdad 10
Frankfurt am Main 10
Hải Dương 10
Phoenix 10
Stockholm 10
Boston 9
Brooklyn 9
Denver 9
Florence 9
Guangzhou 9
Guayaquil 9
Jinan 9
Kunming 9
Poplar 9
Rio de Janeiro 9
Genoa 8
New Delhi 8
Ningbo 8
Pune 8
Riyadh 8
Zhengzhou 8
Amsterdam 7
Haiphong 7
Istanbul 7
London 7
Taizhou 7
Bogotá 6
Chicago 6
Columbus 6
Dhaka 6
Falls Church 6
Figino 6
Houston 6
Kuala Lumpur 6
Totale 6.931
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 191
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 179
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 156
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report 151
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 149
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 146
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 146
Blast phase of essential thrombocythemia: A single center study. 145
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 145
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 139
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS 135
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 135
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 133
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 132
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 131
A gain-of-function mutation of JAK2 in myeloproliferative disorders 131
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 129
Clinical Predictors of Outcome in MPN. 125
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 121
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 119
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 119
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 117
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process 115
JAK2 (V617F) mutation in healthy individuals 113
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. 112
Looking for CALR mutations in familial myeloproliferative neoplasms 112
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 111
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 110
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA 109
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy 109
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 108
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 107
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 107
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 107
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 106
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 106
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 105
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 104
Balancing efficacy and safety of JAK inhibitors in myelofibrosis 103
Leukemia risk models in primary myelofibrosis: an International Working Group study. 101
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 100
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs 100
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 100
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 98
Clinical relevance of JAK2 (V617F) mutant allele burden 97
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 97
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 95
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history 95
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera 95
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases 94
Pomalidomide is active in the treatment of anemia associated with myelofibrosis 94
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 93
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. 91
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY 91
PDGFRB disease: right diagnosis to prolong survival 90
New generation small-molecule inhibitors in myeloproliferative neoplasms 90
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 90
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 90
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. 89
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 89
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 89
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies 89
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients 89
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 88
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. 88
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. 87
How I treat polycythemia vera. 87
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders 87
Leucemia mieloide cronica e sindromi mieloproliferative croniche 86
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. 86
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma 86
How to manage polycythemia vera 84
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project 84
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases 83
Myeloproliferative Neoplasms 82
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment 81
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. 80
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis 80
What are RBC-transfusion-dependence and -independence? 79
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients 79
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients 78
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. 78
Mutational status of myeloproliferative neoplasms. 77
LE NEOPLASIE MIELOPROLIFERATIVE PHILADELPHIA NEGATIVE 77
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 77
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 76
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper 76
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. 76
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. 75
RBC-transfusion guidelines update 75
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 75
Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection 73
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 73
Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi 72
Ruxolitinib and survival improvement in patients with myelofibrosis 72
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 71
It is time to change thrombosis risk assessment for PV and ET? 70
Disease anticipation in familial myeloproliferative neoplasms. 70
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 70
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data 69
Totale 10.071
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.605
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.605
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022482 0 6 11 6 19 11 6 29 21 17 82 274
2022/20231.573 168 96 18 149 150 180 2 102 632 11 32 33
2023/2024537 79 92 16 48 34 157 3 33 4 11 15 45
2024/20251.427 29 127 36 39 40 66 43 117 335 34 229 332
2025/20263.564 280 335 413 347 355 237 663 134 336 273 102 89
2026/2027270 78 192 0 0 0 0 0 0 0 0 0 0
Totale 10.821